Zobrazeno 1 - 10
of 137
pro vyhledávání: ''
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease causing irreparable scarring of lung tissue, resulting in most patients succumbing rapidly after diagnosis. With limited treatment options available, repurposing of current pharmaceuti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::54f8e637282145e804eb409e2ba34f64
https://doi.org/10.1101/2021.12.01.470755
https://doi.org/10.1101/2021.12.01.470755
Autor:
Jimmy L. Zhao, Michael J. Morris, Katia Manova Todorova, Tianhao Xu, Wouter R. Karthaus, Michael C. Haffner, Dana E. Rathkopf, Natasha Rekhtman, Ignas Masilionis, Afsar Barlas, Kristine M. Wadosky, Howard I. Scher, Dana Pe'er, Joachim Silber, Lawrence D. True, Peter S. Nelson, Joseph M. Chan, Ojasvi Chaudhary, Linas Mazutis, Kayla E. Lawrence, Charles L. Sawyers, Ronan Chaligne, David W. Goodrich, Achim A. Jungbluth, Philip A. Watson, Jungmin Choi, Martin P Roudier, Samir Zaidi, Irina Linkov, Anuradha Gopalan
Lineage plasticity is a well–established mechanism of resistance to targeted therapies in lung and prostate cancer, where tumors transition from adenocarcinoma to small–cell or neuroendocrine carcinoma. Through single–cell analysis of a cohort
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0c23edc86fc830f0ed4f2aa44578cb60
https://doi.org/10.1101/2021.11.01.466599
https://doi.org/10.1101/2021.11.01.466599
Autor:
Tong Li, Kerstin E. Braunstein, Ashley Lau, Seth Blackshaw, Jonathan P. Ling, Ronald L. Schnaar, Anabel Gonzalez-Gil, Juan C. Troncoso, Philip C. Wong, Kevin Tu, Tianyu Cao, Alice Wei, Dong Won Kim
It is unknown whether specific microglia are selectively induced by amyloid-β(Aβ), tau pathologies, or both in combination. To address this, we use single-cell RNA-sequencing to profile mice bearing both Aβ and tau pathologies during Alzheimer's d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b62c90c735409d49a77354ada17eb720
https://doi.org/10.1101/2021.10.16.464454
https://doi.org/10.1101/2021.10.16.464454
Autor:
Xing-Mei Zhang, André Ortlieb Guerreiro Cacais, Harald Lund, Keying Zhu, Heela Sarlus, Robert A. Harris, Erik Nutma, Jinming Han, Jingxian Sun, Cindy Bay, Shin-Yu Kung, Sandra Amor, Yang Wang, Keyi Geng, Björn Högberg, Claudia Kutter, Jun Wang
Targeting myeloid cells, especially microglia, for the treatment of neuroinflammatory diseases such as multiple sclerosis (MS), is underappreciated. Here, we screened a library of compounds and identified the topoisomerase 1 (TOP1) inhibitor camptoth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f78caee2c41605c8e79ea32cddc0328
https://doi.org/10.1101/2021.10.04.462880
https://doi.org/10.1101/2021.10.04.462880
BackgroundDurable treatments that benefit a wide pool of patients remain elusive for Non-small cell lung cancer (NSCLC). The success of immunotherapy in a subset of NSCLC patients highlights the potential contribution of immune response to anti-tumor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eedef86090d57667d0fd6c518116c048
https://doi.org/10.1101/2021.10.01.462824
https://doi.org/10.1101/2021.10.01.462824
Autor:
Lihua He, Hong Dang, Scott H. Randell, Rhianna E. Lee, Minges Jt, Lisa C. Morton, Castle Na, Adam J. Kimple, Theile Jw, Michael R. Knowles, Catherine A. Lewis, Gallant Sc, Teresa M. Mascenik
With the approval of elexacaftor/tezacaftor/ivacaftor (trade name Trikafta), the vast majority of people with cystic fibrosis (CF) are eligible for CF transmembrane conductance regulator (CFTR) modulator therapy. Remaining individuals have premature
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2de0779d2aa54a95f1251c245e574cd9
https://doi.org/10.1101/2021.09.28.462149
https://doi.org/10.1101/2021.09.28.462149
Autor:
Alejandro Peñín-Franch, José A García-Vidal, Pablo Pelegrín, Fermín Valera-Garrido, Francesc Medina-Mirapeix, Ana I. Gomez, Francisco Minaya-Muñoz, Pilar Escolar-Reina, Carlos Martinez
The NLRP3 inflammasome coordinates inflammation in response to different pathogen- and damage-associated molecular patterns, being implicated in different infectious, chronic inflammatory, metabolic and degenerative diseases. In chronic tendinopathie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a63e71c7504df56774bd76faf957dce0
https://doi.org/10.1101/2021.09.20.461048
https://doi.org/10.1101/2021.09.20.461048
Autor:
Bertrand Arnulf, Gilles Dadaglio, Véronique Mayau, Antoine Domenger, Ludivine Baron, Jean-Christophe Bories, Caroline Choisy, Ludovic Deriano, Caroline Demangel
Multiple Myeloma (MM) is an incurable malignancy characterized by the uncontrolled expansion of plasma cells in the bone marrow. While proteasome inhibitors like bortezomib efficiently halt MM progression, drug resistance or toxicity inevitably devel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e9c971aa5eb30308bf857ce9162bcb5c
https://doi.org/10.1101/2021.09.05.459026
https://doi.org/10.1101/2021.09.05.459026
Autor:
Tao Dao, Martin G. Klatt, Zita E.H. Aretz, Andrew W Daman, Christopher M. Bourne, Sung Soo Mun, Ron S. Gejman, Katsuyoshi Takata, Christian Steidl, David A. Scheinberg
Exploring the repertoire of peptides presented on major histocompatibility complexes (MHC) has been utilized to identify targets for immunotherapy in many hematological malignancies. However, such data have not been described systematically for diffu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::71ab16e9eb30b0977f84351fc9a1d7cb
https://doi.org/10.1101/2021.09.01.458572
https://doi.org/10.1101/2021.09.01.458572
Autor:
Weijie Zhang, Zeru Tian, Chenfei Yu, Ling Wu, Yuda Chen, Ruchi Gupta, Zhan Xu, Han Xiao, Xiang Zhang, Kuan-Lin Wu
Therapeutic antibodies have gone a long way toward realizing their clinical potential and have become very useful for treating a variety of pathologies. Despite the rapid evolution of therapeutic antibodies, their clinical efficacy in treatment of bo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32ce5a0b1f1fd3b692b6761053aeefe9
https://doi.org/10.1101/2021.08.31.457412
https://doi.org/10.1101/2021.08.31.457412